Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Aion Therapeutic Inc C.AION

Alternate Symbol(s):  ANTCF

Aion Therapeutic Inc is in the business of research and development, treatment, data mining and state-of-the-art artificial intelligence techniques, focused on the development of combinatorial pharmaceuticals, nutraceuticals and cosmeceuticals utilizing compounds from cannabis, psychedelic mushrooms, fungi, natural psychedelic formulations, and other medicinal plants in a legal environment for... see more

CSE:AION - Post Discussion

Aion Therapeutic Inc > Acquisition price of PCAI by Aion
View:
Post by gainwidpatience on Feb 14, 2021 11:14am

Acquisition price of PCAI by Aion

This is the cheapest acquisition ($2.5m) you would see in Psychedelic space! Timing was perfect! Compare with other companies.. at least 25m+

In connection with the Acquisition, the Company entered into a share purchase agreement (the “Share Purchase Agreement”) dated June 26, 2020 between the Company, as purchaser, and the shareholders of 1196691 B.C. Ltd. d/b/a “PCAI Pharma” (the “Parent”), as vendors. Pursuant to the terms of the Share Purchase Agreement, the Company purchased from the vendors and the vendors sold to the Company, all of the issued and outstanding shares (the “Parent Shares”) of the Parent, a company which holds 100% of the issued shares of AI Pharma. In consideration for the Parent Shares, the Company paid to the vendors a purchase price of $2,520,000, which was satisfied by issuing to the vendors an aggregate of 36,000,000 common shares of the Company at a deemed price of $0.07 per share. The transaction was negotiated at arm’s length with the vendors.
Be the first to comment on this post